ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

GNPX Genprex Inc

2.36
0.10 (4.42%)
Fuera de horario
Última actualización: 17:23:52
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Genprex Inc GNPX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.10 4.42% 2.36 17:23:52
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.34 2.2726 2.38 2.36 2.26
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/5/202407:31PRNUSGenprex to Present and Participate at Upcoming May Investor..
09/4/202407:31PRNUSGenprex Collaborators Report Positive Preclinical Data on..
03/4/202407:31PRNUSGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical..
02/4/202407:31PRNUSGenprex Collaborators Publish Positive Preclinical Data with..
22/3/202415:10PRNUSGenprex Announces Closing of $6.5 Million Registered Direct..
19/3/202412:24PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
19/3/202407:36PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
12/3/202408:01PRNUSGenprex Receives Notice of Patent Grant for Korean Patent..
06/3/202408:18EDGAR2Form 8-K - Current report
06/3/202407:30PRNUSGenprex Collaborators to Present Positive Preclinical Data..
26/2/202407:45EDGAR2Form 8-K - Current report
21/2/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202413:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202407:15PRNUSGenprex Expands Nonclinical Programs into New Therapeutic..
06/2/202406:30PRNUSGenprex to Present at Upcoming BIO CEO & Investor Conference
05/2/202407:15EDGAR2Form 8-K - Current report
05/2/202406:30PRNUSGenprex Announces First Patient Dosed in Phase 2a Expansion..
02/2/202406:30EDGAR2Form 8-K - Current report
31/1/202408:00EDGAR2Form 8-K - Current report
31/1/202407:42PRNUSGenprex Announces 1-for-40 Reverse Stock Split Effective..
05/1/202415:17EDGAR2Form 8-K - Current report
05/1/202406:00PRNUSGenprex Provides Business Update and Outlook for 2024
18/12/202315:35EDGAR2Form 8-K - Current report
13/12/202315:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/12/202315:44EDGAR2Form 8-K - Current report
14/11/202310:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202315:19EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
03/11/202315:16EDGAR2Form DEF 14A - Other definitive proxy statements
01/11/202306:30PRNUSGenprex to Present at BIO-Europe 2023 Conference
23/10/202316:01EDGAR2Form PRE 14A - Other preliminary proxy statements
23/10/202315:44EDGAR2Form 8-K - Current report
20/10/202306:30PRNUSGenprex to Host a Virtual Key Opinion Leader Event on..
04/10/202311:00PRNUSGenprex to Present Data on the Use of REQORSA® for the..
25/9/202315:20EDGAR2Form 8-K - Current report
21/9/202307:30GLOBEGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation..
20/9/202307:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
08/9/202315:20EDGAR2Form 8-K - Current report
07/9/202306:30PRNUSGenprex to Present at Upcoming September Investor Conference
01/9/202315:17EDGAR2Form 8-K - Current report
22/8/202306:30PRNUSGenprex Appoints Suzanne Thornton-Jones as Senior Vice..
21/8/202316:13EDGAR2Form 8-K/A - Current report: [Amend]
21/8/202311:47EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15/8/202307:30EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
10/8/202306:30PRNUSGenprex Granted FDA Orphan Drug Designation (ODD) for..
24/7/202311:17EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/7/202315:15PRNUSGenprex Announces Closing of $7.5 Million Registered Direct..
20/7/202315:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/7/202315:06EDGAR2Form 8-K - Current report

Su Consulta Reciente

Delayed Upgrade Clock